Nevro, a Menlo Park, CA-based startup working to develop treatments for chronic pain, has raised $48 million in Series C financing. The raise will be used to further its pivotal clinical study, invest in clinical evidence for new indications and support its international and U.S. commercialization plans. Novo Ventures, a new investor, led the round with participation from New Enterprise Associates, Covidien Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson Development, Mayo Clinic, MPM Capital and Three Arch Partners.
Menlo Park, CA
Provider of pain treatment solutions